These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 18711190)

  • 1. Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma.
    Remák E; Charbonneau C; Négrier S; Kim ST; Motzer RJ
    J Clin Oncol; 2008 Aug; 26(24):3995-4000. PubMed ID: 18711190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic evaluation of sunitinib malate in second-line treatment of metastatic renal cell carcinoma in Finland.
    Purmonen T; Martikainen JA; Soini EJ; Kataja V; Vuorinen RL; Kellokumpu-Lehtinen PL
    Clin Ther; 2008 Feb; 30(2):382-92. PubMed ID: 18343276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma.
    Benedict A; Figlin RA; Sandström P; Harmenberg U; Ullén A; Charbonneau C; Sandin R; Remák E; Hariharan S; Négrier S
    BJU Int; 2011 Sep; 108(5):665-72. PubMed ID: 21265994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of everolimus for second-line treatment of metastatic renal cell carcinoma in Serbia.
    Mihajlović J; Pechlivanoglou P; Sabo A; Tomić Z; Postma MJ
    Clin Ther; 2013 Dec; 35(12):1909-22. PubMed ID: 24238790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A Cost-effectiveness Analysis of Sunitinib vs. Interferon-alpha in Patient with Advanced Renal Cell Carcinoma in Japan].
    Tomura K; Naito Y; Sunaga T; Kurihara T; Usuda M; Nagatani A; Ogawa Y; Akiyama N; Sasaki H; Murata T; Sakamaki H; Kogo M; Sasaki T
    Yakugaku Zasshi; 2018; 138(11):1397-1407. PubMed ID: 30381648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness evaluation of sunitinib as first-line targeted therapy for metastatic renal cell carcinoma in Spain.
    Calvo Aller E; Maroto P; Kreif N; González Larriba JL; López-Brea M; Castellano D; Martí B; Díaz Cerezo S
    Clin Transl Oncol; 2011 Dec; 13(12):869-77. PubMed ID: 22126730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cost-effectiveness analysis of sunitinib in patients with metastatic renal cell carcinoma intolerant to or experiencing disease progression on immunotherapy: perspective of the Spanish National Health System.
    Paz-Ares L; del Muro JG; Grande E; Díaz S
    J Clin Pharm Ther; 2010 Aug; 35(4):429-38. PubMed ID: 20831545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments.
    De Groot S; Blommestein HM; Redekop WK; Sleijfer S; Kiemeney LALM; Oosterwijk E; Uyl-de Groot CA
    PLoS One; 2017; 12(5):e0177364. PubMed ID: 28531203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic evaluation of everolimus versus sorafenib for the treatment of metastatic renal cell carcinoma after failure of first-line sunitinib.
    Casciano R; Chulikavit M; Di Lorenzo G; Liu Z; Baladi JF; Wang X; Robertson J; Garrison L
    Value Health; 2011; 14(6):846-51. PubMed ID: 21914504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How do cost-effectiveness analyses inform reimbursement decisions for oncology medicines in Canada? The example of sunitinib for first-line treatment of metastatic renal cell carcinoma.
    Chabot I; Rocchi A
    Value Health; 2010; 13(6):837-45. PubMed ID: 20561332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of pazopanib versus sunitinib for renal cancer in the United States.
    Delea TE; Amdahl J; Diaz J; Nakhaipour HR; Hackshaw MD
    J Manag Care Spec Pharm; 2015 Jan; 21(1):46-54, 54a-b. PubMed ID: 25562772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of sunitinib in metastatic renal cell carcinoma.
    Purmonen TT
    Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):383-93. PubMed ID: 21831017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness Analysis of Sunitinib versus Interferon-Alfa for First-Line Treatment of Advanced and/or Metastatic Renal Cell Carcinoma in Singapore.
    Pruis SL; Aziz MIA; Pearce F; Tan MH; Wu DB; Ng K
    Int J Technol Assess Health Care; 2019 Jan; 35(2):126-133. PubMed ID: 30854989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.
    Thompson Coon J; Hoyle M; Green C; Liu Z; Welch K; Moxham T; Stein K
    Health Technol Assess; 2010 Jan; 14(2):1-184, iii-iv. PubMed ID: 20028613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic evaluation of sunitinib versus pazopanib and best supportive care for the treatment of metastatic renal cell carcinoma in Chile: cost-effectiveness analysis and a mixed treatment comparison.
    Vargas C; Balmaceda C; Rodríguez F; Rojas R; Giglio A; Espinoza MA
    Expert Rev Pharmacoecon Outcomes Res; 2019 Oct; 19(5):609-617. PubMed ID: 30758237
    [No Abstract]   [Full Text] [Related]  

  • 16. [Economic evaluation of targeted biologic therapy in metastatic renal cell carcinoma].
    Ondrácková B; Demlová R; Komínek J
    Klin Onkol; 2010; 23(6):439-45. PubMed ID: 21351422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of Pazopanib Versus Sunitinib as First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma from an Italian National Health Service Perspective.
    Capri S; Porta C; Delea TE
    Clin Ther; 2017 Mar; 39(3):567-580.e2. PubMed ID: 28189363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of sunitinib in patients with metastatic and/or unresectable gastrointestinal stroma tumours (GIST) after progression or intolerance with imatinib.
    Paz-Ares L; García del Muro X; Grande E; González P; Brosa M; Díaz S
    Clin Transl Oncol; 2008 Dec; 10(12):831-9. PubMed ID: 19068454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of everolimus vs sunitinib in treating patients with advanced, progressive pancreatic neuroendocrine tumors in the United States.
    Casciano R; Chulikavit M; Perrin A; Liu Z; Wang X; Garrison LP
    J Med Econ; 2012; 15 Suppl 1():55-64. PubMed ID: 22881362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom.
    Amdahl J; Diaz J; Sharma A; Park J; Chandiwana D; Delea TE
    PLoS One; 2017; 12(6):e0175920. PubMed ID: 28636648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.